The large array of peptides presented to CD8+ T cells by major histocompatibility complex (MHC) class I molecules is referred to as the MHC class I immunopeptidome. Although the MHC class I immunopeptidome is ubiquitous in mammals and represents a critical component of the immune system, very little is known, in any species, about its composition across most tissues and organs in vivo. We applied mass spectrometry (MS) technologies to draft the first tissue-based atlas of the murine MHC class I immunopeptidome in health. Peptides were extracted from 19 normal tissues from C57BL/6 mice and prepared for MS injections, resulting in a total number of 28,448 high-confidence H2D b /K b -associated peptides identified and annotated in the atlas. This atlas provides initial qualitative data to explore the tissue-specificity of the immunopeptidome and serves as a guide to identify potential tumor-associated antigens from various cancer models. Our data were shared via PRIDE (PXD008733), SysteMHC Atlas (SYSMHC00018) and SWATH Atlas. We anticipate that this unique dataset will be expanded in the future and will find wide applications in basic and translational immunology. 
The large array of peptides presented to CD8+ T cells by major histocompatibility complex (MHC) class I molecules is referred to as the MHC class I immunopeptidome. Although the MHC class I immunopeptidome is ubiquitous in mammals and represents a critical component of the immune system, very little is known, in any species, about its composition across most tissues and organs in vivo. We applied mass spectrometry (MS) technologies to draft the first tissue-based atlas of the murine MHC class I immunopeptidome in health. Peptides were extracted from 19 normal tissues from C57BL/6 mice and prepared for MS injections, resulting in a total number of 28,448 high-confidence H2D b /K b -associated peptides identified and annotated in the atlas. This atlas provides initial qualitative data to explore the tissue-specificity of the immunopeptidome and serves as a guide to identify potential tumor-associated antigens from various cancer models. Our data were shared via PRIDE (PXD008733), SysteMHC Atlas (SYSMHC00018) and SWATH Atlas. We anticipate that this unique dataset will be expanded in the future and will find wide applications in basic and translational immunology. Background & Summary T cells are an essential cell type for next-generation vaccines and immunotherapies 1 . T cells recognize antigens in the form of short peptides presented by MHC (human leucocyte antigen [HLA] in humans) molecules -collectively referred to as the MHC ligandome/peptidome or immunopeptidome [2] [3] [4] . Robust and comprehensive immunopeptidomic profiling of primary cells and tissues is therefore of great importance for the development of effective T-cell based immunotherapies 5 . The cellular immunopeptidome is composed of thousands of MHC-associated peptides-each peptide ranging in abundance between approximately 1 and 10,000 copies per cell 6 . The immunopeptidome can be divided into two main categories: the MHC class I and the MHC class II immunopeptidome. The latter is composed of peptides of 10-25 amino acids in length that are mainly presented on a subset of professional antigen presenting cells. In contrast, the class I immunopeptidome is composed of peptides presented on the surface of virtually any nucleated cell. Class I peptides are generally of 8-12 amino acids in length 7, 8 . In mammals, the composition of the immunopeptidome is complicated by the high diversity of allelic forms 9 . Each allelic form can present a different set of peptides that are characterized by the presence of allele-specific anchor residues, known as MHC binding motif 10 . In humans, more than 17,600 alleles have been documented (IPD-IMGT/HLA Database; December 2017; http://hla.alleles.org/alleles/ index.html) and up to six class I and eight class II alleles can be expressed per cell in each individual. In mouse, >200 alleles are expressed among the most commonly used mouse strains (http://www.imgt.org/ IMGTrepertoireMHC/Polymorphism/haplotypes/mouse/MHC/Mu_haplotypes.html), and up to two class I and two class II alleles can be expressed per cell in each mouse strain. Even though the composition of the immunopeptidome is highly complex in nature, the deployment of robust technology platforms has facilitated the deciphering of the immunopeptidome at increasing depth and robustness 5, 11 . MS is most widely used due to its capability of identifying and quantifying MHC-associated peptides in an accurate, systematic and unbiased manner 12 . In fact, many immunopeptidomics studies have demonstrated the ability of MS workflows to identify thousands of MHC-associated peptides from various biological sources in human, mouse and other species [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Those studies led to a better and systematic understanding of antigen presentation and provided direct physical evidence for the existence of tumor-specific peptides. Nevertheless, only a handful of studies have reported detailed information about the composition of the immunopeptidome in healthy cells and tissues. More specifically, immunopeptidomic analyses of normal thymic cells 24, 25 , peripheral blood mononuclear cells 26 , and spleen and lymph nodes 3, 27 have been documented. Thus, basic information about the identity, abundance and distribution of MHC-associated peptides across normal tissues and organs in healthy humans, mice or other species is still largely missing in the literature.
Design Type(s)
Open and comprehensive reference maps in life sciences, including tissue-based maps, are increasingly beneficial for the scientific community [28] [29] [30] [31] [32] . Similarly, the creation of comprehensive maps of the immunopeptidome in human, mouse, and other species would be of great value for both understanding health and diagnosing, monitoring and treating immune diseases 5 . Given the advances in MS technology over the last decade, the availability of protocols for the isolation MHC-associated peptides from multiple species and tissue types, and the relatively less complex composition of the immunopeptidome in mouse models (in comparison with humans), we reasoned that the time was ripe to initiate a systematic effort to draft the first MS-based atlas of the murine MHC class I immunopeptidome in health using a commonly used mouse strain. To this end, we used data-dependent acquisition (DDA) MS to generate immunopeptidomic data from 19 tissues of healthy C57BL/6 mice. They express both H2D b and H2K b class I molecules (Fig. 1a) . We also mapped the immunopeptidome of four C57BL/6-derived cancer cell lines and used an open and evolving computational pipeline to process the data. Several stringent filters to generate a list of high-confidence H2D b /K b class I peptides for individual tissues and cell lines were applied. All raw/unfiltered MS data as well as H2D b /K b peptide spectral libraries -which consist of consensus spectra calculated from repeat measurement of the same peptide sequence -are made publicly available for re-use and re-processing by the community for in-depth interrogation of the dataset (Fig. 1b) . In summary, the present study provides a unique resource for basic and translational immunologists to navigate the baseline immunopeptidome in mouse. An open reference map of the murine immunopeptidome in health is valuable for i) basic and translational immunologists to rapidly identify disease-specific MHC peptide antigens -through comparison of peptides found in the reference map versus those identified in disease cells -and ii) computational scientists to access a rich source of data to support technical benchmarking of future studies to develop or test new algorithms for immunopeptidomic analyses. In addition, this reference map, together with its connection with SWATH Atlas, lays down the foundation to perform robust quantitative analysis of the murine immunopeptidome using next-generation SWATH/Data-independent acquisition (DIA)-MS technologies 26, 33 .
Methods

Mouse tissues and cell lines
Adrenal gland, bladder, bone marrow, brain, colon, heart, kidney, liver, lung, ovary, pancreas, small intestine, skin, spinal cord, spleen, stomach, testis, thymus, and uterus were extracted from C57BL/6 male or female mice (Annotation Isolation of MHC class I-associated peptides H2D b -and H2K b -associated peptides were isolated by a conventional immunoaffinity purification method using the monoclonal antibodies B22-249.R1 and Y-3, respectively 22 . For generating the tissuebased map of the murine MHC class I immunopeptidome, the tissue/organs from five to six mice were pooled together before isolating MHC-peptide complexes for any given tissue (Annotation Table, Data Citation 1). For each cell line used in this study,~10 9 cells were grown before isolating MHC-peptide complexes. The cell surface abundance of MHC proteins was also quantified for each cell line using the QIFIKIT quantification flow cytometric assay, as previously described 34 .
DDA mass spectrometry
Fragment ion spectra of the respective MHC class I peptide preparations were acquired on an Orbitrap Fusion Lumos and/or a Triple TOF 5600+ (see below) operated in DDA mode. For retention time (RT) normalization and spectral library generation, peptides from the iRT Kit (Biognosys AG, Schlieren, Switzerland) were added to the samples prior to MS injection according to vendor instructions 35 (Data Citation 2).
For Lumos data (Annotation Table, Data Citation 1), peptides were separated on an Acclaim PepMap RSLC C18 column (250 mm x 75 um i.d., 2 Å particle size; ThermoFisher Scientific) using a flow rate of 300 nl min-1 and a linear gradient of 4-29.6% aqueous ACN (with 0.1% formic acid) in 120 min. Full mass spectra were acquired with the Orbitrap analyser operated at a resolving power of 120,000 (at m/z 200). MS/MS spectra were acquired in both HCD and CID mode with a normalized collision energy of 27%. Precursors were selected in the "top speed" mode with a cycle time of 3 s. Fragment ions (charge state 2-6+) were accumulated up to an AGC target value of 50,000 with a maximum injection time of 54 ms and the option "Inject ions for all available parallelizable time" enabled, and were detected in the Orbitrap analyzer at a resolution of 30,000 (at m/z 200). Dynamic exclusion was enabled for 30 s after a selection event with a tolerance of ± 10 p.p.m.
For Triple TOF 5600+ data, (Annotation Table, Data Citation 1). Samples were separated on an Eksigent nanoLC system coupled with an AB SCIEX Triple TOF 5600 + System. The samples were separated in a 75 μm-diameter PicoTip emitter (New Objective, Woburn, MA) packed with 20 cm of Magic 3 μm, 200 Å C18 AQ material (Bischoff Chromatography, Leonberg, Germany). The loaded peptides were eluted from the column at a flow rate of 300 nl/min and a linear gradient of 2-35% aqueous ACN (0.1% formic acid) over 120 min. The mass spectrometer was operated in DDA top20 mode, with 500 and 150 ms acquisition time for the MS1 and MS2 scans respectively, and 20 s dynamic exclusion. MS/MS spectra were acquired in CID mode. Rolling collision energy with a collision energy spread of 15 eV was used for fragmentation.
Database search engines, statistical validation, high-confidence filters and spectral library generation Raw mass spectrometry files were converted into the mzXML format by msConvert 36 . The mzXML files were then individually searched using Comet 37 , MSGF 38 and X!Tandem 39 against the full non-redundant, canonical mouse genome as annotated by the UniProtKB/Swiss-Prot (2014_02) with 20,270 ORFs and appended iRT peptides and reversed decoy sequences. Oxidation at methionine residues was the only variable modification allowed. We used default search settings for all the engines with the following key parameters: Precursor tolerance was set to ±20 p.p.m., high accuracy fragment ion tolerance was set to ±0.02 Da for Comet and 20 p.p.m. for X!Tandem, and digestion specificity was set to unconstrained. The search identifications from different search engines were then combined and statistically scored using PeptideProphet and iProphet within the TPP (4.8.0), as previously described 40 . The probabilities estimated by iProphet was cut at 1% FDR. Then, all 8, 9-mers (for H2K b ) and all 9-11-mers (for H2D b ) were clustered using GibbsCluster (v1.0) 41 -specific peptide spectral libraries were then combined and generated on the peptide atlas level that contains consensus spectra of peptides from different samples. For a given allele-specific spectral library, the same peptide ions generated under various fragmentation methods (CID Orbitrap, CID TOF and HCD) were specified and kept separated as different library entries. The generated spectral libraries were further converted into TraML format and archived in SWATH Atlas for SWATH/DIA-MS analysis.
Data Records
The accession number for the DDA-MS data (raw and centroided mzXML and identified peptides in pepXML report) used to generate the spectral libraries have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository 42 with the dataset identifier PXD008733 (Data Citation 2). Raw and mzXML files are also accessible via the SysteMHC Atlas repository (https://systemhcatlas.org/) 40 with the dataset identifier SYSMHC00018. The The draft map of the murine MHC class I immunopeptidome was generated from 19 different C57BL/6 tissues extracted under steady-state conditions (Fig. 1,Table 1 and Methods). H2D b -and H2K b -peptide complexes were isolated by immunoaffinity purification using the B22-249.R1 and the Y-3 antibody, respectively. Peptides were acid-eluted and acquired in DDA mode using different MS instruments (Table 1) . Following acquisition of data from 280 MS runs, ∼4.8 million MS/MS spectra were searched using a uniform and well-tested computational pipeline 26, 40 (Fig. 1b) and yielded assignments of 681,357 and 850,396 peptide ions with iProphet probability P ≥ 0.9 and P > 0.0, respectively.
Next, we considered all 7-14 mers identified at FDR 1%, resulting in a total number of 81,058 peptides (Supplementary Figure 1) Methods) to remove potential non-MHC binding contaminant peptides. As an example, we observed that after filtering, 72% of all 9-mer H2D b peptides and 81% of all 8-mer H2K b peptides (FDR 1%) identified from spleen tissue were predicted to have a strong MHC binding affinity with IC 50 o500 nM (Supplementary Figure 2a) . Similarly, 80% of all 9-mer H2D b peptides and 80% of all 8-mer H2K b peptides (FDR 1%) identified from heart tissue were predicted to have a strong MHC binding affinity with IC 50 o500 nM (Supplementary Figure 2m) . These data and similar data from other tissue types indicate that the antibodies that were used in this study are relatively specific and the proportion of highconfidence H2D (Fig. 2c) . The different amounts of tissues (in grams) used for immunoprecipitation as well as sample handling may have contributed to this large difference in the number of identified peptides. Nevertheless, we observed that the number of highconfidence peptides identified per tissue generally correlated with the abundance of MHC class I proteins previously reported from the same mouse tissues (Supplementary Figure 3) 43 . Overall 15,645 (2,693 unique) high-confidence H2D b -associated peptides (FDR 1%, 9-11 amino acids, IC 50 o500 nM) and 12,803 (2,594 unique) H2K b -associated peptides (FDR 1%, 8-9 amino acids, IC 50 o 500 nM) were identified (Fig. 2) . The identified peptides mapped to 4,050 of the mouse UniProtKB/Swiss-Prot proteins. Of note, 36.4 and 27.4% of all the high-confidence H2D b -and H2K b -associated peptides were not shared across tissues but were rather exclusively detected in one particular tissue (Table 2 ). In contrast, a relatively small proportion of the measured H2D b immunopeptidome (0.2%) and H2K b immunopeptidome (1.9%) was shared across all the 19 tissues ( Table 2 ). For instance, the H2K b -associated peptides INFDFPKL and VNFEFPEF were found in all the 19 tissues whereas the H2D b -associated peptides AAITNGLAM and HSVINQAVM were found exclusively in the brain. It is important to emphasize, however, that the proportion of tissue-shared and tissue-specific peptides mentioned above were not calculated from quantitative and normalized values. In fact, it is very likely that the low coverage overlap described above would have increased significantly if larger amounts of tissues-for those expressing lower levels of MHC molecules-would have been used for immunoprecipitation. In future studies, it will be important to consider the absolute abundance of MHC molecules per tissue type and adjust/normalize the amounts of starting material accordingly to investigate in a more rigorous manner the tissuespecificity of the MHC class I immunopeptidome. Additional factors such as sample handling, yield of the immunoaffinity purification procedure per tissue type, and limits of detection (LOD) and quantification (LOQ) of mass spectrometers used for identifying MHC-associated peptides would also need to be considered. Taken together, these results delineate the first draft map of the murine H2D The rapid and robust identification of TAAs or tumor-specific antigens is relevant for the development of cancer vaccines, and the generation of a reference map of the MHC class I immunopeptidome in health supports identification of such peptide antigens 5, 34, 44 . In this regard, we compared the list of peptides found in the 19 healthy mouse tissues to those found in several in vitro tumor models. More specifically, we profiled the H2D b -associated peptides were identified in the four tumor cell lines, 2,552 peptides were shared between the healthy tissues and the tumor cell lines, and 730 (22%) peptides were exclusively observed in the tumor cell lines (Fig. 3a) (List of high-confidence H2D b peptides, Data Citation 1) (List of high-confidence H2K b peptides, Data Citation 1). The presence of tumor cell line-specific peptides was also noted. For instance, 28 peptides and 49 peptides were exclusively identified in GL261 and B16F10 cells, respectively (Supplementary Figure 4) . Those peptides might be classified as glioma-and melanoma-associated antigens, respectively, if further tested and validated. Thus, a reference map of the murine immunopeptidome in health guides identification of potential TAAs in model cell lines. We envision that a comprehensive reference map of the murine immunopeptidome in health will find application in tumor immunology and beyond, e.g. in immunopathology to identify a wide variety of disease-specific peptide antigens. /K b peptides were continuously identified as additional MS/MS spectra were collected, suggesting that new peptides will probably be discovered in future experiments, as saturation has not been reached using the presently available technology. Therefore, collecting more data from new experiments (e.g. additional cell lines, additional primary tissues, new experimental conditions, new protocols and MS technologies) will be needed to enable comprehensive and robust quantitative analysis of the murine MHC class I immunopeptidome in the future. In addition, we anticipate that absolute quantitative analysis of immunopeptidomes-i.e. absolute quantification of MHC molecules as well as absolute and systematic quantification of individual MHCassociated peptides per cell and tissue type-will become essential to rigorously assess the completeness of this initial mapping effort.
Sharing H2D
b /K b peptidomic data via SysteMHC Atlas
We anticipate that the dataset generated in this study will be widely used by basic and translational immunologists as well as computational mass spectrometrists. Therefore, an important goal here is to share our immunopeptidomics MS-related data at many different levels of processing. Specifically, we provide raw and converted mzXML files, lists of high-confidence peptides (iProphet results) and H2D b /K b peptide spectral libraries, all available for download from the SysteMHC Atlas (Fig. 3 ) (H2D b /K b peptides used for spectral library generation, Data Citation 1). The SysteMHC Atlas is a new public data repository that serves as a community resource toward the generation of high-quality comprehensive maps of immunopeptidomes and the support of consistent measurements of immunopeptidomic sample cohorts 40 . Until now, the SysteMHC Atlas contains 540 sample/context-and 39 MHC allele-specific peptide spectral libraries (37 HLA and 2 H2 b ), all available for download from the web interface. Moreover, the H2D b -and H2K b -specific peptide spectral libraries generated in this study were both converted into TraML files for robust quantitative analysis of immunopeptidomes using SWATH/DIA-MS, as described previously 26, 45 . TraML files are available at SWATH Atlas (www.swathatlas.org). Notably, three separate fragmentation-specific libraries were created: 1) CID and 2) HCD using the Orbitrap Fusion Lumos, and 3) CID-QTOF using the Triple TOF 5600+ (Fig. 3c) . Different fragmentation methods are complementary and can be used to enhance the identification success rate of MHC-associated peptides and to thus increase immunopeptidome coverage (Fig. 3d) . More importantly, the CID-QTOF-, CID-and HCD-specific spectral libraries support the highthroughput targeted analysis of SWATH/DIA immunopeptidomic data generated by these different fragmentation methods.
In the future, we foresee that continuous development of SysteMHC Atlas for effective sharing and reanalysis of immunopeptidomic datasets will be key to comprehensively define the composition and complexity of the murine immunopeptidome. For instance, we envisage that re-analysis of raw MS data using advanced peptide sequencing algorithms might unveil the presence of non-canonical MHCassociated peptides, e.g. proteasome-spliced peptides 46, 47 (https://www.biorxiv.org/content/biorxiv/early/ 2018/03/26/288209.full.pdf), which would be of particular relevance for the development of peptide-based vaccines and immunotherapies in precision medicine 48 .
Usage notes
The lists of peptides provided in figshare (Data Citation 1) may differ from the ones available at SysteMHC Atlas (https://systemhcatlas.org) 40 . The SysteMHC computational pipeline used to generate the peptide lists is subjected to periodic upgrades and the resulting data may be different from the original publication. To ensure reproducibility of the results, we have introduced a database versioning system and the current build version is 180409 (year/month/date). Current and past builds can also be downloaded at: https://systemhcatlas.org/Builds_for_download/. This information is also available in the 'ABOUT' section of the SysteMHC Atlas website.
